Advertisement

VEGFA Gene Silencing in CXCR4-Expressing Cells via siRNA Delivery by Means of Targeted Peptide Carrier

  • Anna A. Egorova
  • Marianna A. Maretina
  • Anton V. Kiselev
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1974)

Abstract

Discovery of small interfering RNA as a tool for specific gene inhibition led to the development of new therapeutic strategy for the treatment of cancers. The efficacious delivery of therapeutic siRNAs into the cells is a crucial step in RNA interference (RNAi) application, but it remains challenging. Non-viral vectors can provide specific cellular uptake, stable siRNA complex formation, and intracellular siRNA release. Recently, we evaluated modular peptide carrier L1 bearing CXCR4 targeting ligand for its ability to condense siRNA and facilitate endosomal escape and VEGFA gene silencing in CXCR4-expressing endothelial and glioblastoma cells. The present chapter showcases the ability of L1 targeted peptide carrier to form complexes with siRNA and provide efficient VEGFA gene knockdown. We showed that siRNA delivery by means of L1 peptide carrier can result in significant decrease of VEGFA gene expression in A172 glioblastoma cells and in EA.hy 926 endothelial cells. Also, delivery of anti-VEGFA siRNA/peptide complexes led to significant inhibition of endothelial cell migration. Our results showed that L1 peptide carrier modified with CXCR4 ligand is a promising tool for targeted siRNA delivery into CXCR4-expressing cancer and endothelial cells.

Keywords

Cancer gene therapy VEGFA RNA interference Peptide-based carrier CXCR4 Non-viral delivery 

Notes

Acknowledgments

This work was supported by Russian Science Foundation grant 14-15-00737. Marianna Maretina is supported by President of Russian Federation scholarship (SP-822.2018.4).

References

  1. 1.
    Ameres SL, Martinez J, Schroeder R (2007) Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130:101–112.  https://doi.org/10.1016/j.cell.2007.04.037CrossRefPubMedGoogle Scholar
  2. 2.
    Tong AW, Zhang Y-A, Nemunaitis J (2005) Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther 7:114–124PubMedGoogle Scholar
  3. 3.
    Egorova AA, Kiselev AV (2016) Peptide modules for overcoming barriers of nucleic acids transport to cells. Curr Top Med Chem 16:330–342.  https://doi.org/10.2174/1568026615666150812120755CrossRefPubMedGoogle Scholar
  4. 4.
    Boussif O, Lezoualc’h F, Zanta MA et al (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci 92:7297–7301.  https://doi.org/10.1073/pnas.92.16.7297CrossRefPubMedGoogle Scholar
  5. 5.
    Felgner JH, Kumar R, Sridhar CN et al (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 269:2550–2561PubMedGoogle Scholar
  6. 6.
    Huh MS, Lee EJ, Koo H et al (2017) Polysaccharide-based nanoparticles for gene delivery. Top Curr Chem 375:31.  https://doi.org/10.1007/s41061-017-0114-yCrossRefGoogle Scholar
  7. 7.
    Dufès C, Uchegbu IF, Schätzlein AG (2005) Dendrimers in gene delivery. Adv Drug Deliv Rev 57:2177–2202CrossRefPubMedGoogle Scholar
  8. 8.
    Kiselev AV, Il’ina PL, Egorova AA et al (2007) Lysine dendrimers as vectors for delivery of genetic constructs to eukaryotic cells. Russ J Genet 43:593–600.  https://doi.org/10.1134/S1022795407060014CrossRefGoogle Scholar
  9. 9.
    Guryanov IA, Vlasov GP, Lesina EA et al (2005) Cationic oligopeptides modified with lipophilic fragments: use for DNA delivery to cells. Russ J Bioorganic Chem 31:18–26.  https://doi.org/10.1007/s11171-005-0002-zCrossRefGoogle Scholar
  10. 10.
    Juarez J, Bendall L, Bradstock K (2004) Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des 10:1245–1259.  https://doi.org/10.2174/1381612043452640CrossRefPubMedGoogle Scholar
  11. 11.
    Andre F, Soria JC, Assi H et al (2004) Expression of chemokine receptors by cancer cells. Bull Cancer 91(Suppl 4):S254–S256PubMedGoogle Scholar
  12. 12.
    Driessen WHP, Fujii N, Tamamura H, Sullivan SM (2008) Development of peptide-targeted lipoplexes to CXCR4-expressing rat glioma cells and rat proliferating endothelial cells. Mol Ther 16:516–524.  https://doi.org/10.1038/sj.mt.6300388CrossRefPubMedGoogle Scholar
  13. 13.
    Fulton AM (2009) Chemokine receptors in cancer. Humana, New York. ​ https://doi.org/10.1007/978-1-60327-267-4Google Scholar
  14. 14.
    Wang Y, Xie Y, Oupicky D (2016) Potential of CXCR4/CXCL12 chemokine axis in cancer drug delivery. Curr Pharmacol Rep 2:1–10.  https://doi.org/10.1007/s40495-015-0044-8CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kucia M, Reca R, Miekus K et al (2005) Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23:879–894.  https://doi.org/10.1634/stemcells.2004-0342CrossRefPubMedGoogle Scholar
  16. 16.
    Salcedo R, Oppenheim JJ (2003) Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 10:359–370.  https://doi.org/10.1038/sj.mn.7800200CrossRefPubMedGoogle Scholar
  17. 17.
    Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23:7274–7282.  https://doi.org/10.1038/sj.onc.1207947CrossRefPubMedGoogle Scholar
  18. 18.
    Chen S, Feng J, Ma L et al (2014) RNA interference technology for anti-VEGF treatment. Expert Opin Drug Deliv 11:1471–1480.  https://doi.org/10.1517/17425247.2014.926886CrossRefPubMedGoogle Scholar
  19. 19.
    Shubina AN, Egorova AA, Baranov VS, Kiselev AV (2013) Recent advances in gene therapy of endometriosis. Recent Pat DNA Gene Seq 7:169–178.  https://doi.org/10.2174/18722156113079990021CrossRefPubMedGoogle Scholar
  20. 20.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257CrossRefPubMedGoogle Scholar
  21. 21.
    Le Bon B, Van Craynest N, Daoudi J-M et al (2004) AMD3100 conjugates as components of targeted nonviral gene delivery systems: synthesis and in vitro transfection efficiency of CXCR4-expressing cells. Bioconjug Chem 15:413–423.  https://doi.org/10.1021/bc034220oCrossRefPubMedGoogle Scholar
  22. 22.
    Li J, Zhu Y, Hazeldine ST et al (2012) Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion. Angew Chem Int Ed Engl 51:8740–8743.  https://doi.org/10.1002/anie.201203463CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Egorova A, Kiselev A, Hakli M et al (2009) Chemokine-derived peptides as carriers for gene delivery to CXCR4 expressing cells. J Gene Med 11:772–781.  https://doi.org/10.1002/jgm.1366CrossRefPubMedGoogle Scholar
  24. 24.
    Egorova A, Bogacheva M, Shubina A et al (2014) Development of a receptor-targeted gene delivery system using CXCR4 ligand-conjugated cross-linking peptides. J Gene Med 16:336–351.  https://doi.org/10.1002/jgm.2811CrossRefPubMedGoogle Scholar
  25. 25.
    Li J, Lepadatu AM, Zhu Y et al (2014) Examination of structure-activity relationship of viologen-based dendrimers as cxcr4 antagonists and gene carriers. Bioconjug Chem 25:907–917.  https://doi.org/10.1021/bc500191qCrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Li J, Oupický D (2014) Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor. Biomaterials 35:5572–5579.  https://doi.org/10.1016/j.biomaterials.2014.03.047CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Wang Y, Li J, Chen Y, Oupický D (2015) Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes. Biomater Sci 3:1114–1123.  https://doi.org/10.1039/C5BM00003CCrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Wang Y, Li J, Oupický D (2014) Polymeric plerixafor: effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection. Pharm Res 31:3538–3548.  https://doi.org/10.1007/s11095-014-1440-1CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Guo P, You JO, Yang J et al (2014) Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm 11:755–765.  https://doi.org/10.1021/mp4004699CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kiselev A, Egorova A, Laukkanen A et al (2013) Characterization of reducible peptide oligomers as carriers for gene delivery. Int J Pharm 441:736–747.  https://doi.org/10.1016/j.ijpharm.2012.10.020CrossRefPubMedGoogle Scholar
  31. 31.
    Egorova A, Shubina A, Sokolov D et al (2016) CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery. Int J Pharm 515:431–440.  https://doi.org/10.1016/j.ijpharm.2016.10.049CrossRefPubMedGoogle Scholar
  32. 32.
    De Fougerolles A, Frank-Kamenetsky M, Manoharan M et al (2011) IRNA agents targeting VEGF. US Patent No. 7,919,473, 5 Apr 2011Google Scholar
  33. 33.
    Xu H, Jiang B, Meng L et al (2012) N-α-acetyltransferase 10 protein inhibits apoptosis through RelA/p65-regulated MCL1 expression. Carcinogenesis 33:1193–1202.  https://doi.org/10.1093/carcin/bgs144CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Anna A. Egorova
    • 1
  • Marianna A. Maretina
    • 1
    • 2
  • Anton V. Kiselev
    • 1
  1. 1.D.O. Ott Research Institute of Obstetrics, Gynecology and ReproductologySaint-PetersburgRussia
  2. 2.Saint-Petersburg State UniversitySaint-PetersburgRussia

Personalised recommendations